Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, which develops new drugs for patients with rare diseases. Wilson Therapeutics is committed to the development of its lead product, WTX101, which is initially developed as a new treatment for Wilson Disease, a rare genetic disease that causes serious copper poisoning.
Wilson Therapeutics is supported by leading investors, including the following:
HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe. The firm was a founding investor in Wilson Therapeutics.
Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. The company invests across all stages of company development, including early and late-stage private deal, VIPEs (Venture Investments in Public Equities), venture growth and public companies.
MVM Life Science Partners LLP is a premier global healthcare venture capital firm that has been investing in emerging healthcare companies since 1998. Its three funds under management total $500 million and its team of executives is located in London and Boston.
NeoMed Management is an international investment firm, exclusively focused on investments in the healthcare industry. Founded in 1997, NeoMed has established five funds to date and successfully invested in some 40 companies developing or commercialising innovative medical products.